Tema Heart & Health ETF (HRTS) closed at $39.84 on November 4, 2026, up 3.1% from the previous close, on volume of 4,489 shares (30-day average 1,792).
Data as of November 4, 2026.
No headlines found.
No press releases found.
No news found.
Tema Heart & Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions ("CDC"). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test.
Tema Heart & Health ETF trades on the NASDAQ stock market under the symbol HRTS.
As of November 5, 2026, HRTS stock price declined to $39.40 with 2,845 million shares trading.
HRTS has a market cap of $58.31 million. This is considered a Micro Cap stock.
HRTS has outperformed the market in the last year with a price return of +23.0% while the SPY ETF gained +10.8%. HRTS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.1% and +5.0%, respectively, while the SPY returned -3.8% and -4.2%, respectively.
HRTS support price is $39.29 and resistance is $40.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTS shares will trade within this expected range on the day.
